IPO - Alzamend Neuro, Inc.

Form Type: S-1/A

Filing Date: 2025-03-27

Corporate Action: Ipo

Type: Update

Accession Number: 000121465925004902

Filing Summary: Alzamend Neuro, Inc. has filed Pre-Effective Amendment No. 1 to Form S-3 on Form S-1 with the U.S. SEC to convert its existing registration statement into a new registration statement under Form S-1. This prospectus includes the resale of up to 75,775,110 shares of common stock by Orchid Finance LLC, which comprises shares from its Series C Convertible Preferred Stock exchange and warrants. The offering includes shares for which no proceeds will be received by the company from the sales, although exercise of warrants by the Selling Stockholder could yield proceeds. The document details the registration of shares for resale and outlines the usage and sale strategies for those shares. Alzamend is identified as a smaller reporting and emerging growth company. Notable product candidates include AL001 and ALZN002 targeting Alzheimer’s and other neuropsychiatric conditions, reflecting ongoing clinical trials and development goals, while the company is still securing additional funding for ongoing operations and development.

Document Link: View Document